Inulin controls inflammation and metabolic endotoxemia in women with type 2 diabetes mellitus: a randomized-controlled clinical trial.
There is limited evidence on the effects of prebiotics on inflammation. Therefore, the aim of this study was to evaluate the effects of inulin supplementation on inflammatory indices and metabolic endotoxemia in patients with type 2 diabetes mellitus. The participants included diabetic females (n = 49). They were divided into an intervention group (n = 24) as well as a control group (n = 25) and received 10 g/d inulin or maltodextrin for 8 weeks, respectively. Fasting blood sugar (FBS), HbA1c, insulin, high-sensitive C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-α), interleukin-10 (IL-10), and plasma lipopolysaccharide (LPS) were measured pre and post intervention. Inulin-supplemented patients exhibited a significant decrease in FBS (8.5%), HbA1c (10.4%), fasting insulin (34.3%), homeostasis model assessment of insulin resistance (HOMA-IR) (39.5%), hs-CRP (35.6%), TNF-α (23.1%), and LPS (27.9%) compared with the maltodextrin group (p < 0.05). Increase in IL-10 was not significant in inulin compared with the maltodextrin group. It can be concluded that inulin supplementation seems to be able to modulate inflammation and metabolic endotoxemia in women with type 2 diabetes.
Faculty of Nutrition, Student Research Center, Tabriz University of Medical Sciences , Tabriz , Iran .
Parvin
P
Dehghan
Bahram Pourghassem
BP
Gargari
Mohammad Asghari
MA
Jafar-Abadi
Akbar
A
Aliasgharzadeh
D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000191:economics / Q000627:therapeutic use*; D015992:Body Mass Index; D003131:Combined Modality Therapy; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000178:diet therapy* / Q000188:drug therapy / Q000276:immunology; D004311:Double-Blind Method; D019446:Endotoxemia / Q000097:blood / Q000150:complications* / Q000276:immunology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D056747:Immunomodulation; D007333:Insulin Resistance; D007444:Inulin / Q000191:economics / Q000627:therapeutic use*; D007492:Iran; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors / Q000097:blood; D008875:Middle Aged; D009765:Obesity / Q000150:complications* / Q000276:immunology; D050177:Overweight / Q000150:complications* / Q000276:immunology; D056692:Prebiotics / Q000191:economics; D055815:Young Adult
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007004:Hypoglycemic Agents; D008070:Lipopolysaccharides; D056692:Prebiotics; D007444:Inulin